CD4+ count‐dependent concentration–effect relationship of rituximab in rheumatoid arthritis

AIMS: Rituximab is approved in rheumatoid arthritis (RA). A substantial decrease in CD4+ count was observed in responders after a single cycle of treatment. This study aimed to describe and quantifying the influence of CD4+ count depletion on the concentration–response relationship of rituximab in R...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Clin Pharmacol
Autors principals: Bensalem, Amina, Mulleman, Denis, Thibault, Gilles, Azzopardi, Nicolas, Goupille, Philippe, Paintaud, Gilles, Ternant, David
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6955400/
https://ncbi.nlm.nih.gov/pubmed/31454097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14102
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars